Imidazole

Imidazole

SCHEMBL645933

Oc1ccccn1.c1c[nH]cn1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
FKBP5 Q13451 1/20 0.50
LMNA P02545 2/20 0.33
P4HTM Q9NXG6 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
METAP1 P53582 1/20 0.33
BLM P54132 1/20 0.33
HIF1A Q16665 1/20 0.33
DOHH Q9BU89 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HRH4 Q9H3N8 2/20 0.32
HRH3 Q9Y5N1 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dipyridyl SCHEMBL28370248 0.80 KDM4E (0.58) ALDH1A1FKBP5LMNAP4HTMKDM4E
Dipyridyl SCHEMBL7143241 0.80 KDM4E (0.58) ALDH1A1FKBP5LMNAP4HTMKDM4E
Catechol SCHEMBL1927483 0.79 ALDH1A1 (0.59) ALDH1A1FKBP5LMNAKDM4EPOLB
Dipyridyl SCHEMBL3491432 0.78 KDM4E (0.56) ALDH1A1FKBP5LMNAP4HTMKDM4E
SCHEMBL8978433 0.78 KDM4E (0.50) ALDH1A1LMNAP4HTMKDM4ECYP1A2
SCHEMBL29419423 0.78
SCHEMBL18660488 0.78
Dipyridyl SCHEMBL3847534 0.78 KDM4E (0.56) ALDH1A1FKBP5LMNAP4HTMKDM4E
SCHEMBL2355 0.78
Phenol SCHEMBL7155201 0.78 ALDH1A1 (0.56) ALDH1A1FKBP5CES2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858999-B2 IL-17 receptor A antigen binding proteins AMGEN K-A, INC. (US) 2024-01-02 US disclosed
US-20230124150-A1 COMPLEMENT FACTOR Bb ANTIBODIES ALLERGAN, INC. 2023-04-20 US disclosed
EP-4008726-A1 COMPLEMENT COMPONENT C5 ANTIBODIES ALLERGAN, INC. (US) 2022-06-08 EP disclosed
CN-107207585-B Complement component C5 antibody 阿勒根公司 2021-12-21 CN disclosed
EP-3165539-B1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS AMGEN K A INC (US) 2021-12-08 EP disclosed
US-11180564-B2 IL-17 Receptor A antigen binding proteins AMGEN K-A, INC. (US) 2021-11-23 US disclosed
US-20210101965-A1 COMPLEMENT COMPONENT C5 ANTIBODIES XENCOR, INC. 2021-04-08 US disclosed
US-20200362045-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS AMGEN K-A, INC. 2020-11-19 US disclosed
US-20200317762-A1 COMPLEMENT FACTOR Bb ANTIBODIES ALLERGAN INC (US) 2020-10-08 US disclosed
US-10752678-B2 Complement component C5 antibodies ALLERGAN, INC. (US) 2020-08-25 US disclosed
US-6096728-A Composition and method for treating inflammatory diseases AMGEN INC. (US) 2000-08-01 US disclosed
EP-0949931-A1 COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES AMGEN INC. (US) 1999-10-20 EP disclosed
EP-0942740-A2 COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES AMGEN INC. (US) 1999-09-22 EP disclosed
EP-0914431-A2 TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS AMGEN INC. (US) 1999-05-12 EP disclosed
CN-1215340-A Composition comprising interleukin-1 inhibitor and controlled release polymer AMGEN BULDER INC (US) 1999-04-28 CN disclosed
EP-0904112-A1 COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER Amgen Inc., (US) 1999-03-31 EP disclosed
WO-1998024463-A2 COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES AMGEN INC. (US) 1998-06-11 WO disclosed
WO-1998024477-A1 COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES AMGEN INC. (US) 1998-06-11 WO disclosed
WO-1998001555-A2 TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS AMGEN INC. (US) 1998-01-15 WO disclosed
WO-1997028828-A1 COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER AMGEN BOULDER INC. (US) 1997-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200362045-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS IL17A, IL23R, IL15RA ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885
US-11858999-B2 IL-17 receptor A antigen binding proteins IL17A, IL23R, IL15RA ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885
US-11180564-B2 IL-17 Receptor A antigen binding proteins IL17A, IL23R, IL15RA ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.